Eli Lilly is proving that being second but better can also pay. Zepbound, the American firm’s weight-loss jab, was approved in its home country in November 2023, more than two years after Wegovy, made ...

Eli Lilly (LLY.N), opens new tab, the $815 billion maker of blockbuster weight-loss drugs Mounjaro and Zepbound, is trading at more than double the valuation multiple of Wegovy maker Novo Nordisk ...

Amgen’s AMGN stock has declined 10.4% in the past three months. A lot of this price decline is related to the broader ...

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of the medication.

Novo Nordisk (NVO) stock in focus as the company promotes FDA-approved Wegovy as a ban for makers of compounding versions ...

When you first start taking Wegovy, you’ll take a lower dose. Your prescribing healthcare provider will provide you with a dose escalation (titration) schedule that outlines when to increase ...

Ozempic is primarily a diabetes drug, whereas Wegovy is a weight loss drug with a higher dose of semaglutide than Ozempic. Confusing? You betcha. Here’s a quick summary to help. It’s FDA ...

The usual dose of Novo Nordisk’s expensive weight-loss drug Wegovy can be cut in half without affecting the results, ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...

Noom’s documents show that a personalized approach could start with half the typical starter 0.25-milligram dose of Wegovy and gradually increase to about half the FDA-approved maximum dose of 2 ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly. Participants who received tirzepatide also had greater improvements in metabolic risk ...